In an effort to support global initiatives to contain the spread of the new coronavirus (COVID-19), the Academy is presenting Spring 2020 events through online platforms and some of our previously scheduled events are being postponed to a later date. Please check our events listing for the latest information and contact our Customer Service team with any additional questions. For Academy programs and resources about COVID-19, click here.

We are experiencing intermittent technical difficulties. At this time, you may not be able to log in, register for an event, or make a donation via the website. We appreciate your patience, and apologize for any inconvenience this may cause.

This site uses cookies.
Learn more.


This website uses cookies. Some of the cookies we use are essential for parts of the website to operate while others offer you a better browsing experience. You give us your permission to use cookies, by continuing to use our website after you have received the cookie notification. To find out more about cookies on this website and how to change your cookie settings, see our Privacy policy and Terms of Use.


Myasthenia Gravis and Related Disorders II

Edited by Edited by Gil I. Wolfe (University at Buffalo School of Medicine and Biomedical Sciences, Buffalo, New York), Matthew N. Meriggioli (University of Illinois College of Medicine at Chicago, Chicago, Illinois), Emma Ciafaloni (University of Rochester, Rochester, New York), and Robert L. Ruff (Louis Stokes Cleveland Department of Veterans Affairs Medical Center and Case Western Reserve University, Cleveland, Ohio)
Myasthenia Gravis and Related Disorders II

Published: December 2012

Volume 1275

Learn More

Myasthenia gravis (MG), an acquired immune syndrome affecting proteins at the neuromuscular junction, causes significant muscular functional impairment and can compromise patients’ quality of life, including fatigue, disability, and increased mortality rates. Continued efforts in the last decades have begun to produce significant progress in our understanding of this rare condition, yet considerable challenges remain for improving diagnosis and developing effective treatments for MG. The present volume comprises papers stemming from the “12th International Conference on Myasthenia Gravis and Related Disorders,” held May 21–23, 2012 at the New York Academy of Sciences in New York City. The papers collected in this second of two Annals volumes highlight some of the key developments in neuroscience and immunology in MG and related syndromes presented at the conference, including treatment update and what lies ahead, congenital myasthenic syndromes, Lambert-Eaton myasthenic syndrome, the thymus, thymectomy, and the myasthenia gravis thymectomy trial, and hot topics selected from submitted abstracts.